| Authors: |
Dillard CM; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gurumurthi A; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee HC; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thomas SK; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Weber DM; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Orlowski RZ; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KK; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: kpatel1@mdanderson.org., Hildebrandt MAT; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: mhildebr@mdanderson.org. |
